Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322634
Status:
COMPLETED
Last Update Posted:
2012-09-19
First Post:
2006-05-05
Brief Title:
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
Sponsor:
New Mexico Cancer Care Alliance
Organization:
New Mexico Cancer Care Alliance
Study Overview
Official Title:
Investigator Initiated Trial Prospective Study of Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The use of performance status and LDH in combination can predict patient survival more accurately than physician clinical impression or the patients own feelings about their survival
Detailed Description:
Patients with incurable cancer frequently ask their doctors for an estimate of survival Such estimates can assist patients in making decisions about how best to spend their time and energy Survival estimates are also required when considering patients with incurable cancer for experimental treatments However such estimates are difficult to make There is some data to suggest that a simple clinical measure the performance status combined with a laboratory blood test the LDH may assist in making the survival estimate more realistic This study is designed to test if this is the case using patients with metastatic lung breast colorectal prostate or pancreatic cancer or patients with cancer of unknown primary who have exhausted life-prolonging therapy These patients will be asked to consent to entering this study Their performance status will be assessed by the Karnofsky and WHO scales they will be asked to have their blood tested for LDH and they and their doctor will be asked to estimate their survival After study entry they will be allowed to receive palliative radiotherapy surgery or systemic therapy as indicated including protocol treatment After study entry the only other requirement is that the date of the patients death be reported so that the duration of survival can be compared with the doctors and patients estimate and correlated with the performance status and LDH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None